Advertisement

Search Results

Advertisement



Your search for The ASCO Post,The ASCO Post matches 17622 pages

Showing 15701 - 15750


hepatobiliary cancer

Genomic Analyses Point to the Potential of Personalized Care for Liver Cancer Patients

A new study presented at The International Liver Congress™ 2015 in Vienna, Austria, showed that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma, it is possible to identify specific molecular profiles. It is hoped that these ...

solid tumors
lymphoma

Cancer Rates Significantly Increased Among Patients With Hepatitis C

Results presented at The International Liver CongressTM 2015 show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV may be an increased risk of cancer. Study...

NCCN Presents Rodger Winn Award to Daniel G. Coit, MD

At the 20th Annual Conference of the National Comprehensive Cancer Network (NCCN) held in March 2015 in Hollywood, Florida, NCCN presented Daniel G. Coit, MD, with the Rodger Winn Award. The award, named for NCCN’s “founding father” of the Guidelines Program and the first Editor-in-Chief of the...

Expert Point of View: Isaac Brownell, MD, PhD

Isaac Brownell, MD, PhD, Investigator with the Dermatology Branch of the National Cancer Institute, commented on the findings of the Australian ONTRAC trial for The ASCO Post. “This is an interesting finding, and it expands on prior work showing reductions in [ultraviolet]-induced DNA damage and...

skin cancer

Simple Means of Preventing Nonmelanoma Skin Cancer Reported

Two daily doses of nicotinamide, a form of vitamin B3, significantly reduced the occurrence of nonmelanoma skin cancers by 23% in individuals considered at high risk for these lesions in an Australian study. Results of the phase III ONTRAC trial, which will be presented at the 2015 ASCO Annual...

Expert Point of View: Philip L. McCarthy, MD

Another exciting multiple myeloma treatment will be presented at the 2015 ASCO Annual Meeting,” Philip L. McCarthy, MD, Professor of Oncology and Director of the Blood and Marrow Transplant Center at Roswell Park Cancer Institute, Buffalo, New York, commented in an interview with The ASCO Post....

About the Contributors

Ronald Piana is an independent writer and reporter with more than 20 years of experience in oncology communications and publishing. In addition to the profiles published in this special supplemental issue of The ASCO Post, Ron has written more than 100 news and feature articles, interviews, and...

In Memoriam: John H. Saiki, MD

John “Jack” Harris Saiki, MD, Professor Emeritus at the University of New Mexico Department of Medicine, Hematology/Oncology Division, lived the history of modern-day oncology with a career spanning 44 years. In the early days of his career, with the support of a grant from the federally funded New ...

In Memoriam: Dorothy ‘Dottie’ Thomas

Dorothy “Dottie” Thomas was wife and research partner to 1990 Nobel laureate E. Donnall Thomas, MD, pioneer of the bone marrow transplant and former Director of the Clinical Research Division at Fred Hutchinson Cancer Research Center. Dr. and Mrs. Thomas formed the core of a team that proved bone...

In Memoriam: Lee W. Wattenberg, MD

One of the early giants in the field of cancer prevention, Lee W. Wattenberg, MD, published in 1966 what would be regarded as a landmark paper in the American Association for Cancer Research (AACR) journal Cancer Research. During his research, he reviewed 36 years of animal studies, looking at the...

In Memoriam: Jesse L. Steinfeld, MD

In 1971, then Surgeon General Jesse L. Steinfeld, MD, took Big Tobacco to task, stating, “Let me suggest that certain purveyors of cigarettes stop making remarks about how some young mothers in childbirth might welcome smaller babies. The mother who smokes is subjecting the unborn child to the...

In Memoriam: John Michael Fitzpatrick, MCh, FRSCI

John Michael Fitzpatrick, MCh, FRSCI, was one of Europe’s most highly regarded medical opinion leaders. He studied medicine at University College Dublin and did his clinical internship at St. Vincent’s Hospital in Dublin. While doing his residency at St. Vincent’s, he decided to become a urologist, ...

In Memoriam: Eddie Reed, MD

Eddie Reed, MD, was a pioneer in the molecular pharmacology of DNA-damaging anticancer agents and the clinical development of paclitaxel for ovarian cancer. He graduated from Yale University School of Medicine in 1979, completed his internship and residency at Stanford University in 1981, and was...

2015 Oncology Meetings

JUNE 13th International Conference on Malignant Lymphoma (ICML)June 17-20 • Lugano, Switzerland For more information: www.lymphcon.ch/imcl/index.php2 Yale ASCO® Review 2015: Highlights of the Annual MeetingJune 19 • New Haven, Connecticut For more information:...

After a Long and Distinguished Career, Robert C. Young, MD, Shows No Sign of Slowing Down

Robert C. Young, MD, ASCO Past President, longtime leader of Fox Chase Cancer Center, and an internationally recognized expert in lymphoma and ovarian cancer, is a forward-looking doctor who is confident about something not in his future: retirement. “I’ll never quit working; I’m just not wired...

Andrew C. von Eschenbach, MD, Went From the Front Lines of Cancer Care to a Bird’s-Eye View of the Changing Oncology Landscape

At the end of the day, I’m still a kid from South Philly,” Andrew C. von Eschenbach, MD, former Director of the National Cancer Institute (NCI) and Commissioner of the U.S. Food and Drug Administration (FDA), told The ASCO Post. Dr. von Eschenbach is the product of a closely knit yet culturally...

myelodysplastic syndromes

Nationally Recognized Leader in Myeloid Malignancies, Alan F. List, MD, Has High Hopes for the Future of Oncology

The Tampa Bay area of Florida is a haven for golfers and fishermen looking to unwind under the warm tropical skies. And the clean highways stretching through the scenic west coast of Florida are also a perfect excuse for weekend motorcycle enthusiasts, such as Alan F. List, MD, the President and...

lymphoma

Lymphoma Expert and Industry Leader Sandra J. Horning, MD, Pushes the Frontiers of Drug Development and Oncology Research

Due to childhood health issues, Sandra J. Horning, MD, formed an opinion about doctors at a young age: They were good people who helped other people. By her early teens, Dr. Horning began to ponder a career in medicine, which offered the possibility of blending her love of science with a career...

‘Father of Geriatric Oncology’ Lodovico Balducci, MD, Unearthed a New Understanding of Aging’s Effect on Cancer Treatment

At the 2007 ASCO Annual Meeting, Lodovico Balducci, MD, received the inaugural B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology. Called the “patriarch of geriatric oncology,” Dr. Balducci is widely known in the oncology community for his warm humor and thick Italian...

ASCO Announces First-Ever Clinical Trial

ASCO announced its first-ever clinical trial, which will offer patients with advanced cancer access to molecularly targeted cancer drugs and collect “real-world” data on clinical outcomes, to help learn the best uses of these drugs outside of indications approved by the U.S. Food and Drug...

supportive care

Expect Questions About Preventing Fractures After Stem Cell Transplant

Does the finding that the incidence of fractures is “compellingly higher” after hematopoietic stem cell transplantation mean that physicians counseling patients about transplant should feel compelled to discuss the fracture risks? Huifang Linda Lu, MD, PhD, the corresponding author of the study...

issues in oncology
hematologic malignancies
solid tumors

Incidence of Fractures Is ‘Compellingly Higher’ After Hematopoietic Stem Cell Transplantation

The incidence of fractures is “compellingly higher” after receiving hematopoietic stem cell transplantation, according to a retrospective study of patients receiving transplants for treatment of multiple myeloma, other hematologic malignancies, and some solid tumors (mostly breast and ovarian) as...

Gerstner Family Foundation Commits $10 Million to Broad Institute

Broad Institute of MIT and Harvard announced a $10 million gift from the Gerstner Family Foundation, which will expand cancer research at Broad Institute and broaden collaborations with Dana-Farber/Harvard Cancer Center and Memorial Sloan Kettering Cancer Center. The research will focus on the...

Patient Guides Available Through ASCO University Bookstore

ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...

Margaret Foti Recognized as 2015 Honoree of the ‘One Hundred’ by Massachusetts General Hospital Cancer Center

Margaret Foti, PhD, MD (hc), CEO of the American Association for Cancer Research (AACR), was honored for her “dedication and commitment to solving cancer through research” and for her “passionate advocacy for increased federal funding for cancer research and biomedical science,” at Massachusetts...

Meir Wetzler, MD, RPCI Leukemia Chief, Dies at Age 60

Meir Wetzler, MD, Chief of the Leukemia Section at Roswell Park Cancer Institute and University at Buffalo (UB) Professor of Medicine, died on February 23 from injuries sustained during a skiing accident in Colorado. He was 60 years old. Nationally prominent in his field, Dr. Wetzler helped set...

Carol A. Kruse, PhD, Pioneer in Brain Cancer Research and Immunotherapy, Dies at Age 61

Carol A. Kruse, PhD, a University of California, Los Angeles (UCLA) scientist and recognized leader in immunologic therapy for brain cancer, recently passed away in Los Angeles after a 6-month battle with an aggressive form of cancer. She was 61. Dr. Kruse was a UCLA Professor of Neurosurgery and...

Alan C. Sartorelli, PhD, Pioneer in Targeted Chemotherapy and AACR Past President, Dies at Age 83

Alan C. Sartorelli, PhD, Alfred Gilman Professor of Pharmacology at Yale University School of Medicine, Past President of the American Association for Cancer Research (AACR), and a Fellow of the AACR Academy, died on April 30, 2015. A pioneer in cancer chemotherapy, Dr. Sartorelli was one of the...

2015 Oncology Meetings

JUNE The International Society of Ocular Oncology (ISOO) MeetingJune 16-19 • Paris, France For more information: http://www.isoo.org 13th International Conference on Malignant Lymphoma (ICML)June 17-20 • Lugano, Switzerland For more information: www.lymphcon.ch/imcl/index.php2 Yale ASCO® Review...

Martin McMahon, PhD, Joins Research Team at Huntsman Cancer Institute

Martin McMahon, PhD, will join Huntsman Cancer Institute (HCI) at the University of Utah in August 2015 as Professor in the Department of Dermatology and HCI Senior Director of Preclinical Translation. Dr. McMahon is currently the Efim Guzik Distinguished Professor of Cancer Biology at the...

Jonathan L. Finlay, MB, ChB, FRCP, Recipient of the Elizabeth and Richard Germain Endowed Chair in Pediatric Cancer

During the Wyss Family Symposium, hosted by Nationwide Children’s Hospital May 11–12, Jonathan L. Finlay, MB, ChB, FRCP, Director of Neuro-Oncology at Nationwide Children’s, was announced as the first recipient of the Elizabeth and Richard Germain Endowed Chair in Pediatric Cancer. Dr. Finlay is...

Mount Sinai Receives $8.8 Million Grant to Further Stem Cell Research

An $8.8 million grant from the New York State Stem Cell Science Program (NYSTEM) will accelerate efforts by the Icahn School of Medicine at Mount Sinai to develop new stem cell-based treatments for chemotherapy-resistant blood cancer and other genetic blood disorders. Increasing Stem Cells...

issues in oncology

How and When to Give Professional Feedback

Providing students and residents with feedback on their medical performance is a key element in their learning and development and ensures that high standards are met, according to Charlene M. Dewey, MD, MEd, FACP, Assistant Dean of Educator Development; Associate Professor of Medical Education and ...

Five Oncology Researchers Selected as Howard Hughes Medical Institute Investigators

The Howard Hughes Medical Institute announced 26 of the nation’s top biomedical researchers as investigators for the Institute. These scientists will receive the flexible support necessary to move their research in creative new directions. The initiative represents an investment in basic biomedical ...

colorectal cancer

Another Angiogenesis Inhibitor Shows Benefit in Metastatic Colorectal Cancer, but Where Do We Go Next?

The phase III RAISE trial—reported by Tabernero and colleagues in The Lancet Oncology1 and reviewed in this issue of The ASCO Post—demonstrated that ramucirumab ­(Cyramza), a fully human IgG1 monoclonal antibody to the vascular endothelial growth factor receptor 2 (VEGFR2) extracellular domain, in...

Nancy Brinker Named May LUNGevity Hero

The LUNGevity Foundation has announced Nancy Brinker, Founder and Chief of Global Strategy of Susan G. Komen, as the May LUNGevity Hero in recognition of her decades-long dedication and trailblazing work in the fight against cancer. A true pioneer of the advocacy movement, Ms. Brinker gave a...

Daniel D. Von Hoff, MD, FACP, Receives the 2015 Wallace A. Reed, MD, Award

Daniel D. Von Hoff, MD, FACP, Distinguished Professor and Physician-in-Chief of the Translational Genomics Research Institute (TGen), received the 2015 Wallace A. Reed, MD, Award on May 29 from the Arizona Medical Association (ArMA). The award recognizes his accomplishments in advancing innovative...

Roswell Park Cancer Institute Appoints New Leadership Team

Roswell Park Cancer Institute recently announced a restructuring of its leadership. “In many cases, these new appointments represent Roswell Park Cancer Institute parlaying our own existing strengths and talents,” says President and CEO Candace Johnson, PhD. “Restructuring some of these positions...

ASCO 2015—Investigators Announce Patient Enrollment for NCI-MATCH Trial

Investigators for the nationwide trial, NCI-MATCH: Molecular Analysis for Therapy Choice (EAY131), have announced that the precision medicine trial will open to patient enrollment in July. The announcement was made recently during ASCO’s Annual Meeting in Chicago. The MATCH trial seeks to determine ...

Fulfilling NCI’s Commitment to Supporting the Best Science

On April 1, 2015, Douglas R. Lowy, MD, became Acting Director of the National Cancer Institute (NCI), succeeding ­Harold Varmus, MD, who left NCI to join the faculty of Weill Cornell Medical College in New York. (See “The Next Step in a Storied Career,” in the May 25, 2015 issue of The ASCO Post.)...

ASCO Appoints Lidia Schapira, MD, FASCO, Editor in Chief of Patient Information Website, Cancer.Net

ASCO appointed Lidia Schapira, MD, FASCO, a medical oncologist at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, the new Editor in Chief of its award-winning patient information website, Cancer.Net. Dr. Schapira assumed this role at the...

skin cancer

The Promise of Immune Checkpoint Inhibition: Changing the Therapeutic Landscape for Melanoma and Other Malignancies

The past 3 years have witnessed transformative changes in the way that solid tumors and hematologic malignancies are approached, in almost every instance now including consideration of some form of immunomodulation in the first- or later-line therapeutic setting. The greatest success has occurred...

Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman

Kenneth C. Frazier, JD, Chairman and CEO of Merck & Co., Inc., was elected Chairman of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Frazier formerly held the position of Chairman-Elect and succeeds Ian C. Read, Chairman and CEO of Pfizer, Inc. New Officers ...

issues in oncology

New ASCO Journal to Focus on Cancer in Resource-Constrained Countries

Internationally renowned oncologist David Kerr, MD, DSc, will serve as founding Editor-in-Chief of the new ASCO publication, Journal of Global Oncology (JGO). JGO will be the first journal focused exclusively on cancer research, treatment, and care delivery in middle- and low-resource countries...

Institute of Medicine to Become National Academy of Medicine

At its 152nd Annual Meeting on April 28, 2015, the membership of the National Academy of Sciences voted to change the name of the Institute of Medicine to the National Academy of Medicine. The newly named National Academy of Medicine will continue to be an honorific society and will inherit the...

Large Urology Group Practice Association Appoints President-Elect

Neal Shore, MD, FACS, of Atlantic Urology Clinics, LLC, was recently appointed President-Elect of the Large Urology Group Practice Association (LUGPA). “I am honored to be appointed to this prestigious position within [the Association] and look forward to furthering the organization’s goal,...

Eduardo M. Sotomayor, MD, Named Director of GW Cancer Center

The George Washington University (GW) School of Medicine and Health Sciences (SMHS), the GW University Hospital, and the GW Medical Faculty Associates announced the appointment of Eduardo M. Sotomayor, MD, as the inaugural Director of the GW Cancer Center (GWCC). He will also serve as a Professor...

issues in oncology
lung cancer

The Basket Trial: An Evolving Clinical Trial Design

The recently published results of the CUSTOM (Molecular Profiling and Targeted Therapies in Advanced Thoracic Malignancies) trial, reviewed in this issue of The ASCO Post, describe a basket trial focused on identifying molecular biomarkers in advanced non­­–small cell lung cancer (NSCLC), small...

gynecologic cancers

What Is the Future of Intraperitoneal Treatment in Advanced Ovarian Cancer?

An analysis of Gynecologic Oncology Group (GOG) studies recently reported in the Journal of Clinical Oncology by Tewari and colleagues and reviewed in this issue of The ASCO Post showed a survival benefit of intraperitoneal chemotherapy vs intravenous chemotherapy over long-term follow-up in women...

prostate cancer

Studies Evaluate Effectiveness of Active Surveillance in Prostate Cancer Patients

Active surveillance has become a viable option for many men with low-risk prostate cancer who choose not to undergo active treatment such as surgery or radiotherapy. Four studies evaluating the effectiveness, trends, and other considerations for active surveillance in managing prostate cancer were...

Advertisement

Advertisement




Advertisement